Charles River Laboratories International (NYSE:CRL) Issues Earnings Results, Beats Estimates By $0.16 EPS

Charles River Laboratories International (NYSE:CRL) issued its earnings results on Wednesday. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16, Zacks reports. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International updated its FY 2025 guidance to 9.100-9.600 EPS.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $158.02 on Wednesday. Charles River Laboratories International has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $8.08 billion, a PE ratio of 19.76, a price-to-earnings-growth ratio of 5.91 and a beta of 1.37. The stock’s 50-day moving average price is $174.59 and its 200-day moving average price is $189.16.

Analyst Ratings Changes

A number of brokerages recently issued reports on CRL. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. The Goldman Sachs Group reduced their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Barclays reduced their target price on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday. JPMorgan Chase & Co. reduced their target price on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research note on Monday, February 3rd. Finally, Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of “Hold” and an average price target of $197.64.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).